BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5

• Press Releases

  Jenscare Announces 2025H1 Interim Results

  September 1, 2025

   · 

  2 min read
• Press Releases

  Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

  September 1, 2025

   · 

  15 min read
• Press Releases

  Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

  September 1, 2025

   · 

  8 min read
• Press Releases

  Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

  September 1, 2025

   · 

  9 min read
• Press Releases

  Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

  September 1, 2025

   · 

  10 min read
• Press Releases

  New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

  September 1, 2025

   · 

  5 min read
• Press Releases

  Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

  September 1, 2025

   · 

  7 min read
• Press Releases

  New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

  September 1, 2025

   · 

  13 min read
• Press Releases

  Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C

  September 1, 2025

   · 

  11 min read
• Press Releases

  Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

  September 1, 2025

   · 

  11 min read